N/A
Completed N=1,645
Special Survey on Parkinson's Disease Patients Treated Long-term Use of Pramipexole
Source: ClinicalTrials.gov NCT00615914 ↗Enrolled (actual)
1,645
Serious AEs
7.1%
Results posted
Nov 2010
Primary outcomePrimary: Proportion of Adverse Events, Adverse Drug Reactions, Serious Adverse Events — 42.4; 34.5; 7.2 percentage of participants
Summary
The survey is conducted to collect safety and effectiveness information on the use of Pramipexole for long time of period in daily clinical settings in Japan.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Proportion of Adverse Events, Adverse Drug Reactions, Serious Adverse Events |
42.4; 34.5; 7.2 | — |
| SECONDARY Clinical Global Impression of Improvement |
48; 561; 484; 209; 225 | — |
| SECONDARY Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Total Score |
-5.4 | — |
| SECONDARY Change From Baseline in Modified Hoehn & Yahr Rating Scale |
-0.2 | — |
Eligibility Criteria
Inclusion Criteria
Patients with Parkinson's disease
Exclusion Criteria
Patients should have been treated according to the Japanese insert slip
Data sourced from ClinicalTrials.gov (NCT00615914). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.